Product Description
vaccinia immune globulin can reduce corneal scarring that is sometimes associated with serious vaccinia complications and can impair vision
Mechanisms of Action: PPAR-a Agonist
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: National Eye Institute (NEI)
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Vaccinia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| VIG31 | P2 |
Completed |
Vaccinia |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|